State of Alaska Department of Revenue Has $12.16 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

State of Alaska Department of Revenue reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 168,704 shares of the medical equipment provider’s stock after selling 20,525 shares during the period. State of Alaska Department of Revenue’s holdings in Hologic were worth $12,161,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Prentiss Smith & Co. Inc. grew its holdings in shares of Hologic by 0.3% during the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares in the last quarter. Covestor Ltd grew its holdings in shares of Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 145 shares during the last quarter. Finally, Empirical Finance LLC lifted its position in shares of Hologic by 1.8% during the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after buying an additional 147 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Down 10.1 %

NASDAQ HOLX opened at $65.45 on Friday. The business has a 50 day simple moving average of $72.63 and a 200 day simple moving average of $77.86. Hologic, Inc. has a one year low of $64.87 and a one year high of $84.67. The stock has a market capitalization of $14.77 billion, a P/E ratio of 19.65, a P/E/G ratio of 2.35 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.88% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on HOLX shares. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $80.00 to $75.00 in a research report on Thursday. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Finally, Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Nine analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $85.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.